(Cervical Cancer) Libtayo (Cemiplimab) Launched in Japan for Recurrent/Progressive Disease
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- March 30, 2023
- 1 min read
On March 30, 2023, Sanofi Japan announced the commercial launch of Libtayo (cemiplimab) IV infusion, an anti-PD-1 antibody drug, for the treatment of cervical cancer that has progressed or recurred following chemotherapy.
Cervical cancer is most commonly caused by HPV infection. Approximately 80% of cases are squamous cell carcinoma, with the remainder being primarily adenocarcinoma. Treatment options are limited for patients with progressive or recurrent disease.
This approval is based on the EMPOWER-Cervical 1 Phase 3 clinical trial, an international multicenter study enrolling patients (N=608) with recurrent or metastatic cervical cancer. Patients were randomized to receive Libtayo (350 mg every 3 weeks as second-line therapy, N=304) or investigator's choice of chemotherapy (N=304). The primary endpoints were overall survival (OS) and progression-free survival (PFS).
Key Results:
- Median OS: Libtayo 12.0 months vs. chemotherapy 8.5 months — statistically significant improvement
Sanofi Japan stated that the company will continue to collaborate with co-developer Regeneron to bring hope to cervical cancer patients in Japan, and to further contribute to patients, families, and healthcare providers.
Source: https://www.sanofi.co.jp/dam/jcr:0a6fdb34-9135-4f48-9c4a-ff178bcb58fc/230330.pdf
Cervical Cancer | Immunotherapy | Libtayo | Cemiplimab
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4